Dissolving Microneedle Delivery of Nanoparticle Encapsulated Antigen Elicits Efficient Cross-Primming and Th1 Immune Responses by Murine Langerhans Cells


Published in:
Journal of investigative dermatology

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright 2015 Elsevier. This manuscript is distributed under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Dissolving Microneedle Delivery of Nanoparticle Encapsulated Antigen Elicits Efficient Cross-Priming and Th1 Immune Responses by Murine Langerhans Cells

Marija Zaric, Oksana Lyubomska, Candice Poux, Mary Hanna, Maeliosa McCrudden, Bernard Malissen, Rebecca Ingram, Ultan F Power, Christopher J Scott, Ryan F Donnelly, Adrien Kissenpfennig

Cite this article as: Marija Zaric, Oksana Lyubomska, Candice Poux, Mary Hanna, Maeliosa McCrudden, Bernard Malissen, Rebecca Ingram, Ultan F Power, Christopher J Scott, Ryan F Donnelly, Adrien Kissenpfennig, Dissolving Microneedle Delivery of Nanoparticle Encapsulated Antigen Elicits Efficient Cross-Priming and Th1 Immune Responses by Murine Langerhans Cells, Journal of Investigative Dermatology accepted article preview 22 September 2014; doi: 10.1038/jid.2014.415.

This is a PDF file of an unedited peer-reviewed manuscript that has been accepted for publication. NPG are providing this early version of the manuscript as a service to our customers. The manuscript will undergo copyediting, typesetting and a proof review before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

Received 7 April 2014; revised 17 July 2014; accepted 26 August 2014; Accepted article preview online 22 September 2014

© 2014 The Society for Investigative Dermatology
Dissolving Microneedle delivery of Nanoparticle encapsulated Antigen elicits efficient cross-priming and Th1 immune responses by murine Langerhans cells

Marija Zaric¹, Oksana Lyubomska¹, Candice Poux¹, Mary Hanna¹, Maeliosa McCrudden⁵, Bernard Malissen²,³,⁴, Rebecca Ingram¹, Ultan F. Power¹, Christopher J. Scott⁵, Ryan F. Donnelly⁵, *Adrien Kissenpfennig¹

¹The Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, University Road, Belfast, BT9 7AE, UK.

²Centre d’Immunologie de Marseille-Luminy (CIML), Aix Marseille Université, UM2, Marseille, France. ³INSERM U1104, Marseille, France. ⁴CNRS UMR7280, Marseille, France

⁵School of Pharmacy, Queen’s University Belfast, Lisburn Road, Belfast, BT9 7BL, UK.

Corresponding Author

*Dr Adrien Kissenpfennig

Mailing address: Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, University Road, Belfast, BT9 7AE, UK

Telephone number: +44 28 90 97 2295

E-mail: a.kissenpfennig@qub.ac.uk

© 2014 The Society for Investigative Dermatology
Dendritic cells (DCs) of the skin play an important role in skin-mediated immunity capable of promoting potent immune responses. We availed of polymeric dissolving microneedle (MN) arrays laden with nano-encapsulated antigen to specifically target skin DC networks. This modality of immunization represents an economic, efficient and potent means of antigen delivery directly to skin DCs, which are inefficiently targeted by more conventional immunization routes. Following MN immunization, Langerhans cells (LCs) constituted the major skin DC subset capable of cross-priming antigen-specific CD8$^+$ T cells \textit{ex-vivo}. While all DC subsets were equally efficient in priming CD4$^+$ T cells, LCs were largely responsible for orchestrating the differentiation of CD4$^+$ IFN-\(\gamma\) and IL-17 producing effectors. Importantly, depletion of LCs prior to immunization had a profound effect on CD8$^+$ CTL responses \textit{in vivo}, and vaccinated animals displayed reduced protective anti-tumour and viral immunity. Interestingly, this cross-priming bias was lost following MN immunization with soluble antigen, suggesting that processing and cross-presentation of nano-particulate antigen is favoured by LCs. Therefore, these studies highlight the importance of LCs in skin immunization strategies and that targeting of nano-particulate immunogens through dissolvable polymeric MNs potentially provides a promising technological platform for improved vaccination strategies.
INTRODUCTION

Elucidation of the mechanisms that underpin the functional specialization of distinct DC populations is important for the development of improved immunotherapies and the generation of DC-targeted vaccines, particularly in the skin, which represents an attractive site for vaccine delivery (Romani et al., 2010). In normal epidermis, langerin (CD207)-expressing Langerhans cells (LCs) constitute the only population of professional antigen-presenting cells, while the dermis harbours three distinct CD207+ DC subsets: migratory LCs, CD207+CD103+ and CD207+CD103− dermal DCs (dDCs), in addition to two CD207− dDC subsets, characterized by differential expression of CD11b (Henri et al., 2010).

Numerous studies have highlighted significant in vivo functional heterogeneity among skin DC populations. CD207+ dDCs appear to be required for protective immunity in a number of infection and vaccination models, while the precise contribution of LCs in promoting immune responses in vivo remains controversial. Several studies have questioned whether LCs are required for the generation of protective antigen-specific immune responses in different mouse models (Kautz-Neu et al., 2011; Ritter et al., 2004; Zhao et al., 2003), while studies permitting the conditional or constitutive ablation of CD207+ DCs suggest that LCs instigate antigen-specific unresponsiveness or tolerance under homeostatic conditions (Schrwarz et al., 2010; Henri et al., 2010; Idoyaga et al., 2013). Another unresolved question is whether LCs are capable of efficient cross-priming antigen in vivo (Romani et al., 2012), with numerous models attributing this role primarily to CD207+ dDCs and lymph node (LN) resident CD8+ DCs (Igyarto and Kaplan, 2013). LCs have been shown to stimulate type 2 T-helper (Th) cell responses (Nagao et al.,
2009; Stoecklinger et al., 2011; Hauser et al., 1989), however, LCs have been shown to also evoke Th1 cell responses or activate Th17 cells (Duraisingham et al., 2009; Mathers et al., 2009; Igyarto et al., 2011).

In this study, we entrapped the model antigen, ovalbumin (OVA), into Poly-D-L-lactide-co-glycolide (PLGA) nanoparticles (NPs), as these particles were previously shown to have strong immune-modulatory properties and activate DCs to induce efficient T-cell immune responses (Gutierrez et al., 2002; Jaganathan et al., 2006). Previous studies have demonstrated the capacity of model protein antigens, inactivated or subunit vaccines to prime adaptive immunity when delivered via MN arrays (Sullivan et al., 2010; Kim et al., 2012). To this end, we employed biodegradable polymeric dissolvable MNs to specifically target NP-encapsulated antigen to DCs within the different skin compartments to enhance their activation and promote adaptive immunity. Recently, we demonstrated that MN-mediated delivery of nano-encapsulated antigen efficiently targeted skin DCs, which in turn induced efficient T cell responses (Zaric et al., 2013). However, the contribution of individual skin DC subsets in the induction of immune responses using our vaccination strategy was not examined in detail. Utilising skin DC ablation models, we demonstrate that following MN-mediated NP-immunization, LCs are central in cross-priming antigen in vivo and inducing Th1 and Th17 immune responses by antigen-specific CD4+ T cells. Importantly, we highlight the prerequisite for LCs to generate both antigen-specific anti-tumour and anti-viral immune responses following antigen-NPs MN immunization.

RESULTS

LCs are the major population capable of cross-priming CD8+ T cells
To determine the contribution of specific DC subsets following intradermal immunization, dissolvable MNs containing OVA encapsulated nanoparticles (OVA-NPs) were applied to Lang^{eGFP} mouse ears, and DC subsets from pooled auricular LNs were purified by FACS 24h and 72h post-immunization. Skin-derived DCs (CD11c^{+}/MHCII^{high}/CD8^{+}) were sorted into distinct DC subsets on the basis of eGFP, CD103 and Ep-CAM expression (Fig. S1). Following co-culture of purified skin DCs with CFSE-labelled OVA-specific OT-I CD8^{+} or OT-II CD4^{+} T cells, we found that LCs constituted the major subset able to cross-present OVA-NPs, although a low degree of antigen presentation to CD8^{+} OT-I T cells was mediated by other dDC subsets (Fig. 1a-b). In contrast, all skin DC subsets were equally able to efficiently activate and induce CD4^{+} OT-II cell proliferation in vitro (Fig. 1c-d). Due to their observed slower migration to the draining LNs (Kissenpfennig et al., 2005), LCs-induced OT-I and OT-II T cell proliferation peaked at 72h post MN vaccination. Importantly, delivery of TRITC NPs via MN application demonstrated that NPs were equally taken up by all skin DC subsets in vivo (Fig. S2). Therefore, LCs are the predominant skin DC subset that contribute to cross-priming of naïve antigen-specific CD8^{+}T cells following immunization with dissolvable MNs laden with antigen-encapsulated NPs. However, no observed bias by the specific skin DC subsets could be discerned for antigen presentation and/or activation of CD4^{+} T-cells.

**LCs are necessary for optimal cross-presentation in vivo**

To substantiate our findings with ex-vivo skin DCs in an in vivo system, we employed our Lang^{hDTR} model and depleted CD207^{+} DCs prior to immunization (Kissenpfennig et al., 2005). To deplete LCs only, Lang^{hDTR} mice were treated i.p. with a single dose
of diphtheria toxin (DT) 7 days prior to MN immunization, or a supplementary DT dose was given one day prior to immunization to deplete both LCs and CD207+ dDC, consistent with previously published studies (Fig. S3) (Poulin et al., 2007; Bursch et al., 2007; Ginhoux et al., 2007). One day prior to blank NP (b-NP) or OVA-NP immunization, DT untreated or treated Lang^DTR mice were adoptively transferred with CFSE-labelled CD8+ T cells purified from CD45.1 congenic OT-I mice. Expansion of donor CD8+ cells in auricular LNs was analysed 7 days post MN immunization. As expected, efficient expansion of antigen-specific CD45.1+CD8+ T cells was detected following immunization with OVA-NPs compared to mice immunized with b-NPs. In contrast, expansion of OVA-specific CD8+ T cells was significantly reduced in Lang^DTR mice receiving either DT dosing regimes (Fig. 2a). Interestingly, all skin DC subsets had the capacity to induce efficient IFN-γ production among proliferating OT-I cells, notwithstanding that absolute numbers of IFN-γ+OT-I T cells were significantly reduced in the absence of LCs (Fig. 2b).

These observations were substantiated in a genuine in vivo model by examining the expansion of endogenous OVA-specific CD8+ T cells following MN immunization with b-NPs or OVA-NPs. Utilising the same immunization and depletion protocol described above, isolated auricular LN cells were stained with OVA_{257–264}/H-2Kb pentamers specific for the SIINFEKL epitope of OVA protein two weeks post-immunization. MN immunization with OVA-NPs resulted in increased percentages and total numbers of OVA-specific CD8+ T cells in DT-untreated mice compared to mice that had received one or two doses of DT prior to immunization (Fig. 2c), reaffirming the requirement for LCs for optimal cross-presentation of nano-encapsulated antigen following MN intradermal immunization.
LCs promote Th1 and Th17 CD4+ T cell differentiation

To examine T helper immune responses by different skin-derived DC subsets, we adoptively transferred CD45.1+CD4+ OT-II T cells into Lang^hDTR mice prior to DT treatment and MN immunization. No difference in total numbers of donor OT-II cells was observed between mice with LCs, and mice lacking LCs only, or both LCs and CD207+ dDCs (Fig. 3a-b), confirming that both CD207+ and CD207− dDCs were equally capable of presenting OVA-NPs and activating CD4+ T helper cells. The cytokine profile of expanded CD45.1+OT-II T cells revealed that the polarisation of IFN-γ and IL-17A-producing cells necessitated the presence of LCs (Fig. 3c-d), while only a few OT-II cells polarized towards IL-4-producing Th2 cells. Interestingly, in the absence of LCs, the number of donor OT-II cells producing IL-4 was significantly elevated. Of note, we did not observe any notable difference in the induction of Foxp3-producing OT-II T cells in our model. Therefore, the absence of LCs has a profound effect on the development of Th1 and Th17 cells following MN-mediated delivery of nano-particulate antigen.

LCs are necessary for efficient anti-tumour responses following microneedle immunization

We further examined the contribution of LCs in antigen-specific anti-tumour immune responses. Utilising the same depletion and immunization strategy as in previous experiments, Lang^hDTR mice were challenged 3 weeks post MN-vaccination with B16.OVA tumour cells, and tumour growth was monitored thereafter. As expected,
DT-untreated Lang\textsuperscript{hDTR} mice immunized with OVA-NPs were protected against tumour challenge, while all mice immunized with b-NPs exhibited expected tumour growth. In OVA-NPs immunized mice depleted of LCs only, or both LCs and CD207\textsuperscript{+} dDCs, tumours grew at a reduced rate and mice survived longer compared to b-NPs immunized mice (Fig. 4a-b), suggesting that all skin DCs contribute to anti-tumour immunity following MN-mediated intradermal immunization. However, mice with LCs present developed smaller tumours and survived significantly longer than DT-treated animals (Fig. 4a-b), highlighting the importance of LCs for optimal anti-tumour immunity in this model. Furthermore, staining of tumour cell suspensions with OVA\textsubscript{257–264}/H-2K\textsuperscript{b} pentamers identified a clear population of OVA-specific tumour-infiltrating CD8\textsuperscript{+} T cells in DT-untreated mice, which was found to be 3-5 fold reduced in mice lacking LCs or all CD207\textsuperscript{+} skin DCs at the time of OVA-NPs immunization (Fig. 4c). Similarly, the percentages of tumour-infiltrating total CD8\textsuperscript{+} T cells were increased in DT-untreated mice compared to mice that had received one or two doses of DT prior to immunization (Fig. S4).

To determine the contribution of skin DC subsets in evoking therapeutic anti-tumour immunity, DT treated and untreated Lang\textsuperscript{hDTR} mice were first injected into the flank with B16.OVA tumour cells, and on days 4 and 9 following tumour inoculation they were immunized with MNs (Fig. S5). Only tumours from OVA-NPs immunized DT-untreated animals were significantly affected. These tumours were notably smaller compared to tumours from b-NPs immunized mice 15 days post-tumour inoculation, suggesting that the presence of all skin DC subsets in the skin at the time of immunization is necessary for robust anti-tumour activity in a therapeutic setting (Fig. 4d). Mice survival determined by tumour volume end-point between different experimental groups found that irrespective of the presence of LCs, treatments with
OVA-NPs MNs prolonged overall survival of mice compared to mice treated with b-NPs MNs. However, survival was further improved if LCs were present in the skin at the time of OVA-NPs MN immunization (Fig. 4e).

**LCs are required for effective anti-viral responses following microneedle immunization**

To test the capacity of different skin-derived DC subsets to promote protective viral immunity following MN-mediated vaccination in a murine para-influenza virus model, we utilized a recombinant Sendai virus expressing an ovalbumin/red fluorescent fusion protein (SeV\textsuperscript{OVATdT}) (Zaric et al., 2013). Lang\textsuperscript{HDTR} mice were either untreated or treated with DT, immunized with b-NPs or OVA-NPs, and three weeks later intranasally challenged with SeV\textsuperscript{OVATdT}. All b-NPs immunized animals did not survive beyond 6 days post-challenge (Fig. 5a). When depleted of LCs, OVA-NPs immunized mice presented with significantly reduced survival compared to DT-untreated controls that all survived the challenge. Analysis of whole lung cell suspensions revealed significantly increased percentages of SeV\textsuperscript{OVATdT} positive cells in b-NPs immunized mice compared to untreated OVA-NPs immunized animals. Furthermore, there was a 3-5 fold increase in percentages of SeV\textsuperscript{OVATdT} positive cells in mice lacking LCs, or both LCs and CD207\textsuperscript{+} dDCs compared to mice with their full complement of skin DCs (Fig. 5b-c). Lung viral titre measurements confirmed significantly higher viral titres in DT-treated OVA-NPs immunized mice compared to DT-untreated mice, where viral titres were below detection levels (Fig. 5d).

Analysis of lung cell suspensions 6 days post-challenge revealed that OVA-specific CD8\textsuperscript{+} T cells could consistently be detected in the lungs of OVA-NPs immunized
mice (Fig. 5e), while this population was 2-3 fold reduced when LCs or all CD207^+expressing skin DCs were depleted at the time of MN immunization. We did not observe any significant differences in the ability of LCs, or CD207^+ and CD207^-dDC subsets to activate IFN-γ and/or Granzyme B expressing CD8^+ T cells, as the proportion of IFN-γ^+ and Granzyme B^+ OVA-specific T cells remained similar between the different DT treatment groups (Fig. 5f). Collectively, these results demonstrate that the presence of LCs in the skin at the time of immunization with MNs laden with antigen- NPs is essential for promoting the activation and expansion of antigen-specific CD8^+ T cells contributing to the complete protection against pulmonary viral challenge.

Effective LCs cross-presentation is dependent on nano-encapsulation of antigen

Although our results suggest that LCs represented the predominant DC subset capable of cross-priming nano-encapsulated antigen following MN delivery, it was unclear whether preferential activation of antigen-specific CD8^+ T cells by LCs occurred as a consequence of antigen nano-encapsulation or MN-mediated antigen delivery. Therefore, we directly compared the ability of different skin-derived DC subsets to cross-present antigen delivered by MNs, as either a nano-particulate or a non-nano-particulate formulation. MNs containing either OVA-NPs or the comparable amount of OVA were applied to mouse ears, and DC subsets from auricular LNs were purified by FACS 72h post-immunization as previously described. Following co-culture of DC subsets with CFSE-labelled OT-I cells, we confirmed that nano-particulate antigen was again predominantly cross-presented by LCs. In contrast,
MN delivery of soluble OVA demonstrated that CD207⁺CD103⁺ dDCs were the major population responsible for antigen cross-presentation (Fig. 6a). All other skin-derived DC subsets, including LCs, can to some extent, cross-present soluble antigen, however, the degree of T cell activation by these subsets was significantly reduced in comparison to CD207⁺CD103⁺ dDCs (Fig. 6b). Importantly, these experiments suggest that the physical nature of the immunogen could impact the functional specialisation of skin DCs following intradermal immunization. CD207⁺CD103⁺ dDCs were found to have a superior ability to cross-prime soluble antigen, while cross-presentation of nano-encapsulated antigen was strongly favoured by LCs.

**DISCUSSION**

On-going research in skin DC immunobiology, together with development of new technologies for manipulating DCs, highlight their promising potential in the prevention and treatment of various infectious diseases and cancer (Romani et al., 2010). However, skin DCs populations are heterogeneous, composed of phenotypically and functionally diverse subsets and ensuing immune responses may be influenced by the subset of DC involved. Several studies designed to test LC-mediated cross-presentation *in vitro* or *ex vivo* have confirmed their ability to efficiently present exogenously acquired antigen to antigen-specific CD8⁺ T cells (Klechevsky *et al.*, 2010, Stoitzner *et al.*, 2006). In line with Stoitzner *et al.*, we show here that LCs are also able to efficiently cross present nano-encapsulated antigen to OT-I T cells *ex vivo* following MN-mediated OVA-NPs immunization.

Extensive data to demonstrate LC cross-presentation *in vivo* has been limited (Igyarto and Kaplan, 2013). To date, cross-presentation of cutaneous antigen has
been shown to be dependent on CD207⁺ CD103⁺ dDCs (Stoecklinger et al., 2011, Bobr et al., 2010), whilst we observed only modest antigen cross-priming by dDCs following NPs-MN immunization. In addition, we cannot completely exclude that monocyte-derived infiltrating inflammatory DCs (Cheong et al., 2010) played an additional role in cross-priming. However, they have been shown to be poorly represented in the skin DC migratory fraction of lymph nodes, and had reduced capacity for naïve T cell activation in vivo (Tamoutounour et al., 2013). In contrast to nano-encapsulated antigen, our data suggests that delivery of soluble antigen was most efficiently presented by CD207⁺ CD103⁺ dDCs rather than LCs. Indeed, the ability of CD207⁺CD103⁺ dDCs to cross present skin-borne antigens to CD8⁺ T cells have been confirmed in several models, such as keratinocyte-restricted expression of OVA and infection models of Leishmaniasis, Candida albicans, HSV and Vaccinia virus (Henri et al., 2010, Brewig et al., 2009, Igyarto et al., 2011, Bedoui et al., 2009, Seneschal et al., 2014).

The specific downstream intracellular mechanisms following PGLA-NP uptake, antigen processing and presentation by DCs and their activation in our vaccination model remains poorly understood. PLGA NPs have been shown to specifically activate the NLRP3 inflammasome (Yang et al., 2013, Sharp et al., 2009). Microneedle-mediated PLGA-NPs vaccination likely activates DC inflammasome signaling pathways and this could bias the cross-priming capability of LCs. Furthermore, a possible role of Birbeck’s granules, a unique organelle of LCs, in controlling intracellular fate of particulate antigens cannot be dismissed and further investigation into PLGA-NP LC compartmentalization following uptake and induced activation of LCs is warranted.
A recent study, utilising Na-CMC/sucrose dissolvable MN arrays loaded with live recombinant adenovirus vector or Texas Red-Dextran demonstrated that CD8^+ T cell immune responses to adeno-viral vectors or uptake of Texas Red-Dextran was largely attributed to the CD11b^+CD207^- dDC subset (Bachy et al., 2013). Uptake of particulate antigens by DCs is dependent on several antigen-associated properties, such as size, shape, surface charge, hydrophobicity/hydrophilicity, as well as receptor interactions. Indeed, without specific recognition, PLGA-NPs are naturally targeted to DCs through phagocytosis, while adenovirus viral uptake has been shown to be receptor mediated through clathrin-mediated endocytosis and protein kinase C dependent macro-pinocytosis (Hamdy et al., 2011; Meier and Greber, 2003). Likewise, subsequent activation of innate signalling pathways following viral or PLGA NPs internalisation may differ. Interestingly, a recent study demonstrated that following plasmid DNA intradermal vaccination, CD8^+ T cell cross-priming was largely instigated by infiltrating, second generation antigen-expressing LCs (Elnekave et al., 2014). Therefore, the perceived defined functional allocations among distinct skin DC subsets may not necessarily exist, but rather the underlying mechanisms that govern antigen processing, presentation and activation of DCs may influence their subsequent functional properties and the net immune response.

MN delivery of antigen-NPs to skin DCs led to efficient priming of antigen-specific CD4^+ T cells, irrespective of the presence of LCs. However, LCs were primarily required for Th1 and Th17 development. Similarly, it has been shown that direct presentation of C. albicans-derived antigen by LCs was necessary for the generation of antigen-specific Th17 effectors (Igyarto et al., 2011). Contrary, Fujita and co-workers showed that LCs induced IL-22 producing CD4^+ T cells, that at the same time, lacked the expression of IL-17 and IFN-γ (Fujita et al., 2009). Therefore, the
importance of LCs in maintaining mucosal homeostasis, and for Th17 effector responses in our immunization modality would require further confirmation in an appropriate pathogenic model.

Finally, we demonstrate that LCs are necessary for the induction of protective antigen-specific anti-viral and anti-tumour immunity. The absence of LCs had a dramatic effect on the ability of Sendai infected animals to efficiently clear pulmonary viral infection. This is supported by the observation that selective depletion of LCs in vivo at the time of MN vaccination was sufficient to significantly diminish the expansion of antigen-specific infiltrating CD8+ T cells, confirming that dDCs had a secondary contributory role in cross-priming nano-encapsulated antigen. However, dDCs subsets still mediated some delay in tumour growth and prolonged mice survival. In mice immunised with OVA-NPs and depleted of LCs, or both LCs and CD207+ dDCs, tumours grew at a significantly decreased rate and mice survived longer compared to b-NPs immunised mice suggesting that dDCs were in part necessary for effective anti-tumour immunity. Indeed, it has recently been shown that CD207-CD11b- dDCs may be an important contributor to the cutaneous immune environment (Mollah et al., 2014). Moreover, depletion of both LCs and CD207+dDCs showed an appreciable trend in increased tumour volumes and inferior survival in comparison to mice lacking only LCs, indicating that CD207+ dDCs may beneficially contribute to anti-tumour immunity. Therefore, whether LCs alone are sufficient to induce this anti-tumour and anti-viral response or synergy with other DC subsets is required remains to be determined.

Importantly, the fact that tumour and viral challenges were performed 3 weeks post-immunization indicates that LCs were also involved in the induction of memory response. Indeed, we have previously confirmed that OVA-NPs MN immunization
induced antigen specific memory response in mice challenged with tumour cells 3 weeks post vaccination (Zaric et al., 2013). However, more long-term challenge studies are required to confirm this observation.

Despite changing paradigms, LCs remain an essential cell in the immune system of the skin, at least in the context of antigen-NPs delivery through MNs. Emerging nano-technological advances in drug delivery coupled with self-disabling, biodegradable, dissolving MN arrays offers an exciting prospect for delivery of antigens to easily accessible skin DC populations to improve vaccine efficacy. Therefore, these results provide a strong rationale for more in-depth exploration of therapies based on MN-mediated antigen-NP targeting of LCs for the treatment of infectious diseases and tumours.

**MATERIALS AND METHODS**

**Full details of methods are described in SI Materials and Methods.**

**Fabrication of NPs-Loaded MNs**

MNs prepared from aqueous blends of 20% w/w PMVE/MA were fabricated using laser-engineered silicone micro-mould templates (Donnelly et al., 2011). MN arrays (19×19 array, 600 μm height) containing PLGA NPs were prepared as previously described (Zaric et al., 2013).

**Mice**
Transgenic mice, including Lang\textsuperscript{eGFP} reporter mice, Lang\textsuperscript{hDTR} mice (Kissenpfennig \textit{et al.}, 2005), OT-I and OT-II mice (The Jackson Lab, USA) (Hogquist \textit{et al.}, 1994; Barnden \textit{et al.}, 1998) on a congenic CD45.1 C57BL/6 background were housed under specific pathogen-free conditions. All mice employed for experiments were between 6 to 10 weeks old, age and sex matched and were sanctioned in accordance with the UK Home Office and approved by Queen’s University Belfast Animal Welfare and Ethical Review Board.

**MN immunization**

MNIs containing 10 μg OVA encapsulated NPs or b-NPs, or soluble OVA were applied to the dorsal side of both ears. The MNIs were held in place for at least 5 min and then removed.

**Depletion of LCs or CD207\textsuperscript{+} dDCs**

For systemic \textit{in vivo} depletion of CD207\textsuperscript{+} DCs, Lang\textsuperscript{hDTR} mice were injected \textit{i.p.} with 1μg Diphtheria Toxin (DT) (Quadratec Diagnostics Ltd, UK) using the specified timing of application.

**Reagents for Flow Cytometry**

Surface marker expression was assessed by flow cytometry using fluorochrome-conjugated antibodies (BD Biosciences and eBioscience, UK) and PE-labelled K\textsuperscript{b}/SIINFEKL pentamers were purchased from Prolimmune, UK.

**\textit{In vivo} proliferation assays**
Mice were injected i.v. with $10^6$ CFSE-labelled OT-I or OT-II T cells, 24 hours prior to MN immunization. Mice were sacrificed 7 days following MN application, and auricular lymph nodes were harvested for FACS analysis.

**Ex-vivo proliferation assay**

DCs sorted from the auricular LNs 24h or 72h post-MN immunization were co-cultured in triplicates with CFSE-labelled OVA-specific OT-I or OT-II T cells for 60h in a 1:10 ratio, and proliferation of T cells was measured by the decrease of CFSE fluorescence intensity.

**Tumour challenge**

Three weeks following MN immunization, mice were injected s.c. into the flank with $10^5$ B16.OVA tumour cells (Brown *et al.*, 2001; kindly provided by P Stoitzner, Innsbruck). Tumour size was assessed by measuring the short and long tumour diameters using digital callipers. Measurements were stopped when tumour diameter reached maximum allowed dimension of 20 mm and mice had to be euthanized, according to UK Home Office guidelines and Queens University Belfast ethical review committee guidelines.

**Challenge of mice with recombinant Sendai virus-OVA-TdT (SeV\textsuperscript{OVA-TdT})**

Experimental groups of mice were challenged 3 weeks after MN immunization by intranasal instillation of $2\times10^6$ pfu SeV\textsuperscript{OVA-TdT} (Zaric *et al.*, 2013) in 30 µl of PBS and monitored for up to 7 days.

**Statistical analysis**
Bars in figures show the mean ± SEM. All numerical data were analyzed for significant differences between groups by analyses of variance (ANOVA) with Prism software 5.0 (GraphPad Software, Inc.) Probability values are expressed as the following: ***, p < 0.001; **, p < 0.01; and *, p < 0.05.

Conflict of interest

The authors state no conflict of interest.

Acknowledgements

We would like to thank M. McCaigue, D. Schmid, S. Spence D. Fitzgerald and F. Ginhoux for their technical help and advice. The authors were supported by The Department for Employment and Learning of Northern Ireland, and The Wellcome Trust UK (WT088532MA and WT094085MA), and by BBSRC grant numbers BB/FOF/287 and BB/E020534/1.

© 2014 The Society for Investigative Dermatology
References:


© 2014 The Society for Investigative Dermatology


© 2014 The Society for Investigative Dermatology


Figure Legends

**Figure 1:** All skin-derived DC subsets present antigen to CD4⁺ T cells, but LCs are the major population capable of cross-priming CD8⁺ T cells *ex-vivo*. Mice (n=20) were immunized through MNs with OVA-NPs, and following 24h or 72h defined subsets of DCs from auricular LNs were purified by FACS. 5x10⁴ OVA-specific CD8⁺ or CD4⁺ T cells were co-cultured in triplicates with 5x10³ DCs of each subset for 60h. a) Representative histograms of CFSE dilutions of OT-I cell proliferation. b) Bars graphs representing the percentage of proliferating OT-I T cells. c) Representative histograms of CFSE dilutions of OT-II cell proliferation. d) Bars graphs representing the percentage of proliferating OT-II T cells. Data have been pooled from two separate experiments.

**Figure 2:** LCs are the major skin DC subset capable of antigen cross-presentation *in vivo* Lang⁺HDT mice that were either untreated (DT-) or treated with DT once (DT+) or twice (DT++), received i.v. 10⁶ CFSE-labelled, CD45.1 OT-I cells. Mice were immunized with b-NPs or OVA-NPs the following day and skin-draining LNs were harvested 7 days later. a) Percentages and total numbers of CD45.1⁺OT-I cells recovered within each experimental group are shown. b) CFSE and expression of IFN-γ among CD8⁺CD45.1⁺ cells (*left panel*) and total numbers of IFN-γ producing OT-I cells within each group are shown (*right panel*). c) Percentages and total numbers of endogenous OVA₂₅₇₋₂₆₄/H2Kᵇ⁺CD8⁺ T cells detected in the auricular LNs among different experimental groups are shown. All flow cytometry dot plots represent an individual mouse from each experimental group obtained in one out of three separate experiments.
Figure 3: LCs promote Th1 and Th17 CD4+ T cell differentiation. DT-untreated or treated Lang^{hDTR} mice received i.v. 10^6 CD45.1 OT-II cells. Mice were immunized with b-NPs or OVA-NPs the following day and skin-draining LNs were harvested 7 days later. 

**a)** Percentages and total numbers of CD45.1^+CD4^+T cells recovered within each experimental group are shown. 

**c)** Total LN cells were re-stimulated with PMA-Ionomycin prior to intracellular staining. The expression of IFN-γ and IL-4 among CD4^+CD45.1^+ gated cells is shown. 

**c)** The same as in **b)**, but the expression of IL-17 and Foxp3 among different experimental groups is shown. 

**d)** Total numbers (mean ± SEM, n=6/group) of IL-4, IFN-γ, IL-17, IL-10 or Foxp3 expressing OT-II cells within each group.

Figure 4: LCs are necessary for efficient anti-tumour responses. Lang^{hDTR} mice were DT-treated or untreated and immunized with b-NPs or OVA-NPs MNs. Three weeks later, mice were inoculated s.c. with B16.OVA melanoma cells. 

**a)** Tumour volume measurements (±SEM, n=9/group) over 18 days among experimental groups. 

**b)** As in **a)**, but percentages of survival among different groups are shown. 

**c)** Percentages of OVA-specific, among tumour infiltrating CD8^+ T cells, between experimental groups are shown. 

**d)** Lang^{hDTR} mice, DT-treated or untreated, were injected s.c. with 10^5 B16.OVA cells, and 4 and 9 days later, immunized with b-NPs or OVA-NPs. Tumour volumes (±SEM) among different treatment groups over 15 days post-inoculation are shown. 

**e)** As in **d)**, but percentages of survival among treatment groups (n=9/group) are shown.

Figure 5: LCs are required for effective anti-viral immunity 

**a)** Lang^{hDTR} mice, either DT-untreated or treated, were immunized with b-NPs or OVA-NPs MNs. Mice were challenged i.n. with SeVoVATdT 3 weeks later. Survival among experimental
groups following SeV\textsuperscript{OVATdT} challenge (n=8-10/group) is shown. b) Representative dot-plots indicating percentages of SeV\textsuperscript{OVATdT} positive cells in total lung cell suspensions between groups 6 days post-infection. c) Bars indicating percentage of SeV\textsuperscript{OVATdT} positive cells in total lung cell suspensions between groups (n=10/group). d) Viral titres in lung homogenates between groups at 6 days post-infection. e) Percentages of OVA-specific CD8\textsuperscript{+}T cells infiltrating the lungs between immunization groups. f) IFN-\(\gamma\) and/or Granzyme B production following PMA/Ionomycin re-stimulation of OVA-specific CD8\textsuperscript{+}T cells infiltrating the lungs, as analysed 6 days post SeV\textsuperscript{OVATdT} challenge.

Figure 6: CD207\textsuperscript{+}CD103\textsuperscript{+} dDCs preferentially cross-present soluble antigen delivered following microneedle immunization. Mice (n=20/group) were immunized through MNs with OVA-NPs or soluble OVA, and following 72h defined subsets of DCs from auricular LNs of both immunization groups were purified by FACS. 3-5\times10^{4} OVA-specific CD8\textsuperscript{+} T cells were co-cultured in triplicates with 3-5\times10^{3} DCs of each subset for 60h. a) Representative histograms of CFSE dilutions of OT-I cell proliferation among both immunization groups are shown. b) Bars graphs representing the percentage of proliferating OT-I T cells. Data have been pooled from two separate experiments and are represented as mean ± SEM.